Nutra Pharma Provides Updates on Improvements of Manufacturing Capabilities
Nutra Pharma is providing updates on their work in improving manufacturing scale and capabilities for the production of their over-the-counter pain relievers
Plantation, Florida--(Newsfile Corp. - May 27, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Equine Pain-Away™ and Luxury Feet™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is providing updates today on increasing their manufacturing capabilities for the production of their line of over-the-counter pain relievers and anti-inflammatory drugs.
"We announced earlier this year that we have been in the process of bringing all of our manufacturing in-house," stated Brent Bonner, Warehouse Manager of Nutra Pharma. "As part of this process, we have completed the design and purchase for a new liquid filling line," he continued. "This includes automatic filling, capping, coding, labeling and heat shrinking for most of our products. The new equipment will allow production of up to 40 bottles per minute, which greatly increases our manufacturing capacity. The equipment is expected to be validated, certified and in production by early July. This will allow us to scale up production to meet expected upcoming orders as we increase our sales promotional activities and plan our retail rollout later this year," he concluded.
In addition to Amazon, Walmart Marketplace and the Company's own product websites; Nutra Pharma announced previously their plans to greatly expand online marketing and promotional activity through the use of endorsements from actual product users that include celebrities, internet influencers as well as professional and Olympic athletes.
As Nutra Pharma moves forward with these projects, they will provide further updates throughout the rest of 2021.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin®, Equine Pain-Away™, Luxury Feet™ and Pet Pain-Away™. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The purchase of the new filling line should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Nutra Pharma Corp.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/85494